Home › Autoimmune Diseases › New York › Rochester
Autoimmune Diseases clinical trials in Rochester, NY
4 studies for Autoimmune Diseases are looking for participants at sites in and around Rochester (within about 30 miles). Open a study to see who can join and how to contact the study team.
RESET-SLE: A Phase 1/2 Open-Label Study to Evaluate the Safety and Efficacy of CABA-201 in Subjects With Active Systemic Lupus Erythematosus
RecruitingPhase 1/2
- University of Rochester, Rochester
RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis
RecruitingPhase 2/3
- University of Rochester, Rochester
RESET-MG: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Generalized Myasthenia Gravis
RecruitingPhase 1/2
- University of Rochester Medical Center, Rochester
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
RecruitingObservational study
- Strong Memorial Hospital/University of Rochester, Rochester
About Autoimmune Diseases
Autoimmune diseases are where your immune system attacks healthy cells in your body by mistake. Learn about the symptoms, tests, and treatments.
More about Autoimmune Diseases on MedlinePlus
Autoimmune Diseases trials in other cities
- Houston, TX21 studies
- New York City, NY19 studies
- Washington, DC19 studies
- Philadelphia, PA16 studies
- Durham, NC15 studies
- Boston, MA13 studies
- Los Angeles, CA12 studies
- Chicago, IL12 studies
- Dallas, TX9 studies
- Portland, OR8 studies
- Milwaukee, WI8 studies
- Cleveland, OH8 studies
Other studies in Rochester
- Acute Myeloid Leukemia16 studies
- Cancer (all types)15 studies
- Breast Cancer15 studies
- Lung Cancer15 studies
- Obesity14 studies
- Overweight13 studies
- Non-Small Cell Lung Cancer13 studies
- Prostate Cancer10 studies
- Metastatic Cancer8 studies
- Multiple Myeloma8 studies
- Pancreatic Cancer7 studies
- Bladder Cancer7 studies
From ClinicalTrials.gov, data retrieved Oct 1, 2026. Each study sets its own eligibility; the study team decides who can join.